NeoGenomics, Inc. announced the availability of PanTracer Pro, a new addition to the PanTracer Family, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patients with advanced-stage solid tumors.
As precision oncology continues to evolve, clinicians face growing diagnostic complexity, increasing biomarker requirements, and mounting pressure to initiate treatment quickly, often before a complete molecular profile is available. Fragmented testing workflows, sequential ordering, and tissue limitations can delay care and introduce uncertainty at critical decision points. PanTracer Pro was developed to address these challenges more comprehensively and earlier in the diagnostic pathway.
PanTracer Pro integrates broad, comprehensive genomic profiling (CGP) with diagnosis-directed immunohistochemistry (IHC) and ancillary testing selected based on tumor type. By delivering comprehensive, guideline-aligned insights through a single coordinated order, PanTracer Pro enables physicians to ensure relevant biomarkers are assessed upfront rather than through multiple, sequential tests. Turnaround time for the test is 8–10 days, supporting timely real-world treatment decisions.
Beyond streamlining test selection, PanTracer Pro may help identify clinically relevant biomarkers that can be missed with incomplete testing. The ability of PanTracer Pro to combine broad DNA and RNA sequencing across more than 500 cancer-related genes with tumor-specific ancillary testing supports therapy selection, helps identify potential clinical trial options, and facilitates personalized treatment planning based on a patient’s unique tumor biology. When tissue samples are insufficient or unavailable, cases can automatically reflex to PanTracer LBx, NeoGenomics’ pan-solid tumor liquid biopsy assay, allowing clinicians to continue diagnostic workup without restarting the process.
